Citations

Clear

815 citation(s) found for "Tang, Yu".

Rare Case of Primary Dural Based Marginal Zone B-Cell Lymphoma Camouflaging as Mild Focal Dura Thickness and Pachymeningeal Enhancement (1386)
Hrachova, Maya , Kong, Xiao–Tang

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1386 Get It

Predicting Tempo of Post-Progression Disability Accumulation in Multiple Sclerosis (P02.147)
Soldan, M. Paz, Tang, Junger, Zeid, Nuhad Abou, Kale, Nilüfer , Crusan, Daniel J. , Atkinson, Elizabeth J. , Pirko, Istvan, Keegan, Mark , Lucchinetti, Claudia F. , Noseworthy, John H., Kantarci, Orhun H. , Tütüncü, Melih , Sıva, Aksel , Pittock, Sean J. , Rodriguez, Moses , Weinshenker, Brian G.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p02.147 Get It

Ovarian resection in anti-NMDAr encephalitis: A comparison of aggressive and conservative approaches (S41.006)
Iyengar, Yajur , Hébert, Julien , Muccilli, Alexandra, Wennberg, Richard , Tang‐Wai, David F. , Climans, Seth , Day, Gregory S.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.633 Get It

IRF4 Rewires Tumor Metabolism with Functional Implications on the Immune Microenvironment in Lymphoma
Wenzl, Kerstin , Hachfeld, Christine, Mukherjee, Prithviraj , Tang, Xinyi , Weivoda, Megan , Novak, Anne J. , Ansell, Stephen M. , Mondello, Patrizia , Bhardwaj, Vaishali , Olson, Joshua, Novak, Joseph P. , Yang, Zhi-Zhang , Graham, Nicholas Alexander , Pasqualucci, Laura , Shlomchik, Mark

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 1643-1643

10.1182/blood-2023-178120 Get It

Reprogramming of cellular metabolism is a hallmark of cancer leading to improved cellular fitness and providing a selective advantage to malignant cells. Recently, we found that follicular lymphoma (FL) patients with poor prognosis display increased transcriptional and protein expression of IRF4 (IRF4 high), altered immune signaling and an immunosuppressive tumor microenvironment (TME). Furthermore, high expression of IRF4 rewired B cell metabolism towards glycolysis ( Mondello P et al, Blood 2022;140 Suppl 1:168-169). However, it's unknown whether this metabolic reprogramming may be responsible in part for the impairment of immune cells in the TME, which also rely on glucose for their proliferation and function. Using RNA-seq on 88 FL patients, we found a negative correlation between IRF4-regulated genes associated with glycolysis and tumor infiltration by major immune cell subsets in IRF4 high compared to IRF4 low tumors ( Fig 1A), suggesting that IRF4-driven tumor glycolysis may reinforce an immune suppressed phenotype. Especially, we observed that ALDOA and GPI genes were inversely correlated with expression of CD4 + T cells (r=0.34, p=0.003; and r=0.38, p=0.015, respectively) and T reg cells (r=0.3, p=0.05; and r=0.35, p=0.027, respectively) in IRF4 high but not in IRF4 low tumors. As radioactive glucose is the cornerstone of PET assessment, we investigated the correlation between baseline SUV values and IRF4 expression. Remarkably, we found significantly higher levels of FDG uptake in FL IRF4 high compared to IRF4 low cases (p= 0.003), supporting the glycolytic features of Iymphoma expressing IRF4. To define the metabolic activity and function of lymphoma cells with different IRF4 status, we performed seahorse assay in TMD8 and SUDHL2 cells (lymphoma cells with IRF4 high expression) transfected with siIRF4 or siCtr for 72 hours. In line with the IRF4-dependence on glycolysis, TMD8 transfected with siCtr had a low baseline glycolytic ECAR, while the same value doubled after silencing IRF4. Notably, after adding oligomycin, which stimulates glycolysis, TMD8 control cells showed a lower glycolytic capability compared with those deprived of IRF4, probably due to the already maximal addiction to glycolysis ( Fig 1B left). We then investigated the glycolytic demand of germinal center (GC) B cells differently expressing IRF4. Using irf4 fl/fl mice ( Klein et al, Nat Immunol 2006) crossed with Cγ 1cre animals ( Cγ 1cre; irf4 fl/fl) to induce conditional deletion of irf4 in GC B cells, we tested ex-vivo sorted GC B cells from Cγ 1cre; irf4 fl/fl, Cγ 1cre; irf4 fl/+ and WT mice immunized for 10 days. This time point is critical for studying IRF4 as it corresponds to the GC reaction peak when GC B cells express elevated IRF4 levels promoting terminal differentiation to plasma cells. As expected, GC B cells minimally relied on glycolysis and showed a low ability to respond to oligomycin in WT mice ( Weiser et al, Nat Immunol 2020). However, GC B cells with partial or complete loss of irf4 demonstrated a superior ability to response to increased glycolytic demand ( Fig 1B right), further supporting the conclusion that IRF4 influences B cell dependency on glycolysis. As the malignant cell metabolism can alter nutrient availability in the TME, we explored if lymphoma cells differently expressing IRF4 may change glucose levels in the media and in turn impact T cells activity. We found low glucose and high lactate levels in the media of cell lines with IRF4 high expression, while the opposite was observed for those that were IRF4 low. We then cocultured primary human CD4 + T cells with TMD8 cells transfected with either siIRF4 or siCtr for 3 days at three different concentrations of D-glucose: high (22.2 mM, Gluc hi), normal (5.5 mM, Gluc nor) or absent (0 mM, Gluc nil). In line with our prior findings, coculture of B cells in which IRF4 was knocked out showed a significant decrease in abundance of T reg cells and an increase in T FH cells compared to control in presence of Gluc hi or Gluc nor. In contrast, there was no difference in the overall amount of either T cell subtype irrespective of IRF4 status with Gluc nil, supporting the prerequisite of microenvironmental glucose as primary fuel for T cell survival and function. In conclusion, IRF4 rewires the metabolism in B cells with profound functional implications on the TME. Our data suggest that glucose metabolism represents a functional vulnerability that might be exploited therapeutically.
IRF4 Expression in Germinal Center and Lymphoma B Cells Regulates Antigen-Dependent Immune Response
Mukherjee, Prithviraj , Dasari, Surendra , Hachfeld, Christine, Tang, Xinyi , Weivoda, Megan , Ansell, Stephen M. , Mondello, Patrizia , Nelson, Geoffrey M. , Bhardwaj, Vaishali , Yang, Zhi-Zhang , Wang, Zhiquan , Shlomchik, Mark , Pasqualucci, Laura , Adelman, Karen

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4142-4142

10.1182/blood-2023-174580 Get It

A substantial subset of follicular lymphoma (FL) patients has an early relapse with a poor outcome. We showed that this unfavorable group displays increased expression of IRF4, dysregulated immune signaling and an immunosuppressive microenvironment. At the molecular level, IRF4 controls expression of antigen presentation and immune molecules (e.g. HLA-DR, CD40, PDL1). Furthermore, silencing of IRF4 triggers anti-lymphoma immunity ( Mondello P et al, Blood 2022;140 Suppl 1:168-169). However, little is known on the molecular mechanisms whereby IRF4 controls the crosstalk between B and T cells. To address this question, first we performed RNA-seq, ATAC-seq and CUT&TAG of active (H3K27Ac, H3K4me3) and repressive (H3K27me3, H3K4me1) histone marks in TMD8 and HBL1 (lymphoma cells with high IRF4 expression) transfected with two pairs of siIRF4 or siCtr for 72 hours. Gene expression revealed a broad change in transcription, with 432 upregulated genes and 136 downregulated genes in siIRF4 compared to siCtr. Notably, the genes with increased expression following IRF4 silencing coded for antigen presentation, immune molecules and cytokines (e.g. HLA-DR, CD86, IL6, IL10). Accordingly, we observed significant enrichment of antigen presentation, interferon and immune response signatures ( Fig 1A). Integrating RNA-seq with chromatin accessibility showed a significant shift towards transcriptional upregulation at genes nearest to upregulated ATAC peaks, with significant enrichment at enhancers (n=771). Conversely, transcriptional suppression was enriched at enhancers (n=2,458) of downregulated peaks. k-means analyses of all union peaks, generated by merging ATAC with CUT&TAG peaks, revealed a significant gain of H3K4me3, with concordant loss of H3K4me1 at enhancers with upregulated gene expression. In contrast, H3K4me3 was severely decreased at suppressed peaks. TF motif analysis revealed an enrichment for PU.1 and E2A at IRF4-bound regions, suggesting their cooperation in regulating immune signaling. Since antigen presentation and other immune molecules are critical components of the immune synapse, we explored the role of IRF4 on the interaction between germinal center (GC) B and T cells by crossing irf4 fl/fl mice with conditional deletion of irf4 ( Klein et al, Nat Immunol 2006) and Cγ 1cre mice ( Cγ 1cre; irf4 fl/fl) to induce recombination in GC B cells. After 10 days of immunization (GC reaction peak), Cγ 1cre; irf4 fl/fl and Cγ 1cre; irf4 fl/+ GC B cells showed significant increase of HLA-DR and CD40 expression compared to WT. As expected, Cγ 1cre; irf4 fl/fl mice displayed a significantly skewed light-zone:dark-zone ratio in favor of increased dark-zone, which are the cells that most reflect the action of BCL6, with concordant suppression of plasma cells. Additionally, we observed a significant increase of CD4 + T cells after partial or complete deletion of irf4, with upregulation of T FH cells and decrease of T reg cells ( Fig 1B). Notably, mice with loss of irf4 showed a significant decrease in exhausted T FH cells. To test if this effect was dependent on MHC:TCR interaction, we cocultured CD4 + T cells with TMD8 cells transfected with two siIRF4 or siCtr in presence of blocking antibodies for MHC class I, MHC class II or both. Blocking one or the other MHC class I or II partially rescued the IRF4 effect on T reg and T FH cells respectively as well as reduced anti-lymphoma cytotoxicity. Further experiments blocking IRF4-dependent IL6 and IL10 identified these two cytokines as responsible for the additional effects on T cells. To confirm this as an antigen-dependent immune response we coculture sorted GC B cells from NP-OVA-immunized Cγ 1cre; irf4 fl/fl, Cγ 1cre; irf4 fl/+ and WT mice with CSFE-labeled OVA-specific OT-II CD4 + T cells at a ratio of 2:1 in an organoid system for 5 days. We observed induced antigen specific proliferation of CD4 + T cells in the presence of Cγ 1cre; irf4 fl/fl and Cγ 1cre; irf4 fl/+ GC B cellscompared to WT,as indicated by decrease in CSFE expression . We confirmed an increase of T FH cells and a decrease of T reg cells, supporting the conclusion that IRF4 directly controls the antigen-dependent immune response . In summary, IRF4 expression in GC and lymphoma B cells regulates immune signaling with PU.1 and E2A, thereby modulating antigen-dependent immune responses with potential implications for lymphomagenesis. Future studies investigating targeting of IRF4 in lymphoma are warranted.
Abstract B013: Identification of a Notch transcriptomic signature for breast cancer
Braune, Eike-Benjamin, Wang, Liewei , Leon‐Ferre, Roberto A. , D’Assoro, Antonino B. , Seshire, Anita , Wienke, Dirk , Geist, Felix , Tang, Xiaojia , Kalari, Krishna R. , Boughey, Judy C. , Ingle, James N. , Goetz, Matthew P. , Wang, Kang , Foukakis, Theodoros , Lendahl, Urban

Mayo Clinic

Molecular Cancer Therapeutics | December 1, 2023 | Volume: 22 | Issue: 12_Supplement | Pages: B013-B013

10.1158/1535-7163.targ-23-b013 Get It

Abstract Background: Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therapy are largely lacking. A transcriptomic signature of Notch signalling would thus be warranted, and in this report, we have established such a classifier. Methods: To generate the signature, we first identified Notch-regulated genes from six basal-like breast cancer cell lines subjected to elevated and reduced Notch signalling by culturing on immobilized Notch ligand Jagged1 or blockade of Notch by g-secretase inhibitors, respectively. From this cadre of Notch-regulated genes, we developed candidate transcriptomic signatures that were trained on a breast cancer patient dataset (the TCGA-BRCA cohort) and a broader breast cancer cell line cohort and sought to validate in independent data sets. Results: An optimal 20-gene transcriptomic signature was selected. We validated the signature on two independent patient datasets (METABRIC and Oslo2) and it showed an improved coherence score and tumour specificity compared with previously published signatures. Furthermore, the signature score was particularly high for basal-like breast cancer, indicating an enhanced level of Notch signalling in this subtype. The signature score was increased after neoadjuvant treatment in the PROMIX and BEAUTY patient cohorts, and a lower signature score generally correlated with better clinical outcome. Conclusions: The 20-gene transcriptional signature has the potential to better stratify patients and to evaluate the response of future Notch-based therapies for breast cancer. Citation Format: Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna Kalari, Judy Boughey, Liewei Wang, Roberto A. Leon-Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke, Urban Lendahl. Identification of a Notch transcriptomic signature for breast cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B013.
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
Sun, Jie , Narasimhan, Harish , Cheon, In Su , Qian, Wei , Li, Chaofan , Goplen, N. , Wu, Yue , Wei, Xiaoqin , Son, Young Min , Yao, Changfu , Canderan, Glenda , Kadl, Alexandra , Cannon, Abigail R. , Young, Samuel , Hannan, Riley, Bingham, Grace C. , Chaudhari, Arka Sen, Pramoonjago, Patcharin , Woodfolk, Judith A. , Li, Chaofan , Goplen, Nicholas P , Wu, Y , Yao, Changfu , Zang, Chongzhi , Sun, Jie , Hu, Shengen Shawn , Parimon, Tanyalak , Fink, Elizabeth , Santos, Gislane de Almeida , Tang, Jinyi , Muehling, Lyndsey M. , Cannon, Abigail, Arish, Mohammad, Sturek, Jeffrey M , Shim, Yun M. , Chen, Peter

Mayo Clinic

No container title available | November 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3587418/v1 | PMID 38077031 Get It

Abstract The long-term physiological consequences of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are rapidly evolving into a major public health concern. The underlying cellular and molecular etiology remain poorly defined but growing evidence links PASC to abnormal immune responses and/or poor organ recovery post-infection. Yet, the precise mechanisms driving non-resolving inflammation and impaired tissue repair in the context of PASC remain unclear. With insights from three independent clinical cohorts of PASC patients with abnormal lung function and/or viral infection-mediated pulmonary fibrosis, we established a clinically relevant mouse model of post-viral lung sequelae to investigate the pathophysiology of respiratory PASC. By employing a combination of spatial transcriptomics and imaging, we identified dysregulated proximal interactions between immune cells and epithelial progenitors unique to the fibroproliferation in respiratory PASC but not acute COVID-19 or idiopathic pulmonary fibrosis (IPF). Specifically, we found a central role for lung-resident CD8+ T cell macrophage interactions in maintaining Krt8hi transitional and ectopic Krt5+ basal cell progenitors, thus impairing alveolar regeneration and driving fibrotic sequelae after acute viral pneumonia. Mechanistically, CD8+ T cell derived IFN-γ and TNF stimulated lung macrophages to chronically release IL-1β, resulting in the abnormal accumulation of dysplastic epithelial progenitors and fibrosis. Notably, therapeutic neutralization of IFN-γ and TNF, or IL-1β after the resolution of acute infection resulted in markedly improved alveolar regeneration and restoration of pulmonary function. Together, our findings implicate a dysregulated immune-epithelial progenitor niche in driving respiratory PASC. Moreover, in contrast to other approaches requiring early intervention, we highlight therapeutic strategies to rescue fibrotic disease in the aftermath of respiratory viral infections, addressing the current unmet need in the clinical management of PASC and post-viral disease.
Standardizing nomenclature in regional anesthesia: an ASRA-ESRA Delphi consensus study of upper and lower limb nerve blocks
El‐Boghdadly, Kariem , Albrecht, Éric , Wolmarans, Morné , Mariano, Edward R. , Kopp, Sandra L. , Perlas, Anahi , Thottungal, Athmaja , Tulgar, Serkan , Adhikary, Sanjib Das , Barrington, Michael J. , Blanco, Rafael, Boretsky, Karen , Breebaart, Margaretha , Laurent, David Burckett-St , Carvalho, Brendan , Chin, Ki Jinn , Coppens, Steve , Costache, I. , Dam, Mette , Desmet, Matthias , Egeler, C., Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Fox, Ben, Franco, Carlo D. , Gautier, Philippe , Grant, Stuart A. , Grape, Sina , Guheen, Carrie R., Hebbard, Peter , Hernandez, Nadia , Hogg, Rosemary , Holtz, Margaret, Ihnatsenka, Barys , Ilfeld, Brian M. , Kalagara, Hari , Kessler, Paul, Kwofie, Kwesi , Le-Wendling, Linda , Lirk, Philipp , Ludwin, Danielle, Macfarlane, Alan , Μakris, Alexandros , McCartney, Colin J. L. , McDonnell, John G., McLeod, Graeme , Memtsoudis, Stavros G. , Merjavy, Peter , Moran, EML , Nader, Antoun , Neal, Joseph M. , Niazi, Ahtsham U. , Njathi-Ori, Catherine , OʼDonnell, Brian D. , Oldman, Matt, Orebaugh, Steven L. , Parras, Teresa, Pawa, Amit , Peng, Philip , Pulos, Bridget P. , Saporito, Andrea , Sauter, Axel R. , Sebastian, Maria Paz , Sinha, Sanjay K. , Stimpson, James, Tang, Raymond , Tsui, Ban C. H. , Turbitt, Lloyd , Uppal, Vishal , Geffen, Geert J. van, Vermeylen, Kris , Vlassakov, Kamen, Volk, Thomas , Xu, Jeff L. , Elkassabany, Nabil , Kopp, Sandra , Tulgar, Serkan , Adhikary, Sanjib , Altıparmak, Başak , Bloc, Sébastien , Boretsky, Karen , Bowness, James , Carvalho, Brendan , Chin, Ki Jinn , Chuan, Alwin , Costache, Ioana , Dam, Mette , Dhir, Shalini , Elsharkawy, Hesham , Bendtsen, Thomas Fichtner , Franco, Carlo D , Grape, Sina , Harbell, Monica W , Hebbard, Peter , Ilfeld, Brian M , Ip, Vivian H Y , Johnson, Rebecca L , Kwofie, M Kwesi , Le-Wendling, Linda , Lobo, Clara , Macfarlane, Alan James Robert , Makris, Alexandros , McLeod, Graeme , Memtsoudis, Stavros G , Moran, E M Louise , Nader, Antoun , Neal, Joseph M , Niazi, Ahtsham U , Orebaugh, Steven L , Pawa, Amit , Peng, Philip , Porter, Steven B , Sala-Blanch, Xavier , Sauter, Axel R , Schwenk, Eric S , Sebastian, Maria Paz , Soffin, Ellen M , Tsui, Ban C H , Turbitt, Lloyd , Uppal, Vishal , van Geffen, Geert J , Vermeylen, Kris , Vlassakov, Kamen , Xu, Jeff L , Elkassabany, Nabil M , Mariano, Edward R , El-Boghdadly, K , Volk, Thomas , Kalagara, Hari , Albrecht, Eric , Coppens, Steve , Wolmarans, Morné , Gadsden, Jeff , Aguirre, José Alejandro , Agur, Anne Maria Reet , Bedforth, Nigel M. , Blanco, Rafael, Chelly, Jacques E. , Chuan, Alwin , Harbell, Monica W. , Ip, Vivian , Johnson, Rebecca L. , Kessler, Paul, Lobo, Clara , Porter, Steven B. , Sala‐Blanch, Xavier , Schwenk, Eric S. , Sidhu, Navdeep S. , Soffin, Ellen M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 22, 2023 | Volume: 49 | Issue: 11 | Pages: 782-792

10.1136/rapm-2023-104884 | PMID 38050174 Get It

Background Inconsistent nomenclature and anatomical descriptions of regional anesthetic techniques hinder scientific communication and engender confusion; this in turn has implications for research, education and clinical implementation of regional anesthesia. Having produced standardized nomenclature for abdominal wall, paraspinal and chest wall regional anesthetic techniques, we aimed to similarly do so for upper and lower limb peripheral nerve blocks. Methods We performed a three-round Delphi international consensus study to generate standardized names and anatomical descriptions of upper and lower limb regional anesthetic techniques. A long list of names and anatomical description of blocks of upper and lower extremities was produced by the members of the steering committee. Subsequently, two rounds of anonymized voting and commenting were followed by a third virtual round table to secure consensus for items that remained outstanding after the first and second rounds. As with previous methodology, strong consensus was defined as ≥75% agreement and weak consensus as 50%–74% agreement. Results A total of 94, 91 and 65 collaborators participated in the first, second and third rounds, respectively. We achieved strong consensus for 38 names and 33 anatomical descriptions, and weak consensus for five anatomical descriptions. We agreed on a template for naming peripheral nerve blocks based on the name of the nerve and the anatomical location of the blockade and identified several areas for future research. Conclusions We achieved consensus on nomenclature and anatomical descriptions of regional anesthetic techniques for upper and lower limb nerve blocks, and recommend using this framework in clinical and academic practice. This should improve research, teaching and learning of regional anesthesia to eventually improve patient care.
Epigenetic Reprogramming Drives Epithelial Disruption in Chronic Obstructive Pulmonary Disease
Yeung‐Luk, Bonnie , Wally, Ara, Swaby, Carter, Jáuregui, Sofia, Lee, Esther , Chen, Daniel , Luk, S., Upadya, Nisha, Tieng, Ethan, Wilmsen, Kai , Sherman, Ethan, Sudhakar, Dheeksha, Luk, Matthew, Shrivastav, Abhishek, Christenson, Stephanie A. , Ortega, Victor E. , Biswal, Shyam , Huang, Yvonne J , Tang, Wan-Yee , Sidhaye, Venkataramana K , Christenson, Stephanie A , Zhang, Rachel , Cao, Shuo , Ghosh, Baishakhi

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | November 17, 2023 | Volume: 70 | Issue: 3 | Pages: 165-177

10.1165/rcmb.2023-0147oc | PMID 37976469 Get It

Abstract Chronic obstructive pulmonary disease (COPD) remains a major public health challenge that contributes greatly to mortality and morbidity worldwide. Although it has long been recognized that the epithelium is altered in COPD, there has been little focus on targeting it to modify the disease course. Therefore, mechanisms that disrupt epithelial cell function in patients with COPD are poorly understood. In this study, we sought to determine whether epigenetic reprogramming of the cell-cell adhesion molecule E-cadherin, encoded by the CDH1 gene, disrupts epithelial integrity. By reducing these epigenetic marks, we can restore epithelial integrity and rescue alveolar airspace destruction. We used differentiated normal and COPD-derived primary human airway epithelial cells, genetically manipulated mouse tracheal epithelial cells, and mouse and human precision-cut lung slices to assess the effects of epigenetic reprogramming. We show that the loss of CDH1 in COPD is due to increased DNA methylation site at the CDH1 enhancer D through the downregulation of the ten-eleven translocase methylcytosine dioxygenase (TET) enzyme TET1. Increased DNA methylation at the enhancer D region decreases the enrichment of RNA polymerase II binding. Remarkably, treatment of human precision-cut slices derived from patients with COPD with the DNA demethylation agent 5-aza-2′-deoxycytidine decreased cell damage and reduced air space enlargement in the diseased tissue. Here, we present a novel mechanism that targets epigenetic modifications to reverse the tissue remodeling in human COPD lungs and serves as a proof of concept for developing a disease-modifying target.
BIOM-37. EXTRACELLULAR VESICLES AS A PHARMACODYNAMIC REPORTER IN GLIOBLASTOMA
DeLuca, Valerie , Tang, Nanyun , Hao, Yue , Raju, Anjali, Shaffer, Charles, Riviere-Cazaux, Cécile , Pirotte, Patrick, Keuren‐Jensen, Kendall Van , Burns, Terry C. , Sarkaria, Jann N. , Parney, Ian F. , Berens, Michael E.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v12-v12

10.1093/neuonc/noad179.0048 Get It

Abstract Development of a non-invasive test that can measure drug delivery and target engagement in GBM represents an opportunity to enhance knowledge during early phase clinical trials of a new compound’s pharmacological suitability and potential efficacy. We present here data supporting that the cargo within extracellular vesicles (EV) can potentially serve as a liquid biopsy that reports on the pharmacodynamics of GBM therapeutics. We treated short-term PDX cultures with vehicle, temozolomide, MLN4924, or arsenic trioxide. EVs were isolated from culture supernatants using size exclusion chromatography and then analyzed by mass spectrometry (proteomics) and RNA sequencing to characterize and compare cargo profiles for each condition. We found that at the proteome level, FDFT1 and FARSB were detected only in temozolomide EVs across all cell lines. In addition, there were drug-agnostic indications of exposure, including decreased abundance in all treated EV conditions of SLC3A2, C3, PLG, and A1BG, and increased abundance of GSTP1. These cargo changes were further validated by western blotting and ExoView immunofluorescence on isolated EVs. At the EV-transcriptome level, depending on treatment, there were shared alterations in EV cargo between models in the expression of long non-coding RNAs, genes that are overrepresented in biological processes such as cytoplasmic translation and cellular macromolecule biosynthesis, and circular RNAs. Thus, these results indicate that EV cargo post-treatment may be a novel pharmacodynamic reporter in GBM. To allow immunoprecipitation of patient GBM-derived EVs with the selective interrogation, the potential biomarkers, including PTPRZ1, B7H3, IL13RA2, and EGFR were screened across isolated EVs from both pre-clinical and clinical patient samples. Future efforts are focused on evaluating immunoprecipitated GBM-EVs from longitudinally collected patient biofluids. Overall, we anticipate that the results of this study will lead to development of a clinical test that reflects BBB penetration and tumor response, which will likely aid in novel drug development efforts.